The first Hepatitis C virus self-test, the OraQuick HCV, made by OraSure Technologies, has been prequalified by the World Health Organization (WHO).
This product, meant for laypeople, is an extension of the pre-qualified OraQuick® HCV Rapid Antibody Test developed by OraSure Technologies. It comes in a single kit with all the items needed to perform a self-test.
Hepatitis C, an inflammation of the liver is caused by the hepatitis C virus. This virus causes acute and chronic hepatitis, with severity ranging from a minor disease.
Dr. Meg Doherty, WHO Director of the Department of Global HIV, Hepatitis, and STI Programmes, stated that by the end of 2022, just 36% of the 50 million people living with hepatitis C had obtained a diagnosis, and only 20% had received curative treatment.
“By ensuring that more people receive the diagnosis and treatment they need, the addition of this product to the WHO prequalification list offers a safe and effective way to expand HCV testing and treatment services, ultimately contributing to the global goal of HCV elimination,” said Dr. Doherty.
WHO Director Rogério Gaspar underlines the need for a WHO-prequalified HCV self-test to increase access to quality health goods in low- and middle-income countries and achieve the 90% HCV infection diagnosis goal.WHO Director Rogério Gaspar underlines the need for a WHO-prequalified HCV self-test to increase access to quality health goods in low- and middle-income countries and achieve the 90% HCV infection diagnosis goal.
Mostly spread by needlestick injuries, injectable drug use, healthcare facilities, unscreened blood transfusions, and sexual activities that involve blood, viral hepatitis claims 3,500 lives each day.
By 2030, the WHO aims to completely eradicate HCV as a significant public health issue, emphasizing innovative strategies like self-testing. This approach empowers people to take the initial step toward diagnosis and treatment, ensuring a world where HCV no longer poses a serious danger to public health.
Source:WHO
